HYPMY · Hypermarcas S.A.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HYPMY
this stock
Hypermarcas S.A.
|
$2.80B | -3.9% | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.48B | +35.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$54.01B | +11.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$50.93B | +39.9% | +4.3% | 99.2 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HYPMY | +1.5% | -21.2% | -9.8% | +2.3% | -3.9% |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | -1.8% | -19.3% | -11.3% | +2.1% | -14.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.